LUNG CANCER

Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.

In an interview with Targeted Oncology™, Patricia Rich, MD, discussed the data presented at ASCO 2023 and other recent trials that she found most exciting and important to the field of NSCLC treatment.

The transformative potential of antibody drug conjugates in NSCLC treatment is discussed, encompassing their design, bystander effect, biomarkers, and impact on the treatment landscape.

Dr. Florez and Dr. Sabari discuss standards of care for different patient populations in NSCLC.

Jonathan W. Goldman, MD, discusses the use of osimertinib in the first line setting for patients with non–small cell lung cancer.

Hatim Husain, MD, discussed with participants the case of a patient with lung adenocarcinoma.

In the second part of a 2-part article series, Kartik Konduri, MD, discusses the outcomes of targeting the KRAS G12C mutation in patients with metastatic NSCLC.

During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed with participants what therapy to use, including adjuvant immunotherapy, for a patient with stage III non–small cell lung cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Clinical Case Forum™ event, Ronan J. Kelly, MD, MBA, discussed the significance of the CheckMate 9LA, KEYNOTE-407, EMPOWER-Lung 3, and POSEIDON studies which all explored immunotherapies in patients with advanced non–small cell lung cancer.

Without requiring additional therapy, 2 patients with non–small cell lung cancer treated with THIO and cemiplimab remained free of disease progression in the phase 2 THIO-101 study.

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.

A review of recently updated data from KEYNOTE-671, focused on perioperative use of pembrolizumab in early-stage non–small cell lung cancer.

Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.

Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).

David S. Hong, MD, discusses which disease subgroups may benefit from treatment with larotrectinib.

In the first of a 2-part article series, Kartik Konduri, MD, discusses the data behind the use of adagrasib and sotorasib for patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.

During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed options including concurrent chemoradiation therapy and neoadjuvant therapy for a patient with stage IIIA lung adenocarcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Christopher G. Azzoli, MD, discussed treatment options appropriate for a patient who received surgical resection for stage IIB lung adenocarcinoma.

Data from a phase 1 dose escalation study showed tolerability and antitumor activity with IBI351 in patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed practice management strategies as a thoracic medical oncologist, including multidisciplinary care, communication between inpatient and outpatient oncology services, and advice on end-of-life care.

The phase 3 LUNAR trial evaluating tumor treating fields with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer.

Phase 2 results have placed a novel EGFR exon 20 insertion inhibitors in the realm of possibilities for future treatment of previously-treated non–small cell lung cancer with EGFR exon 20 insertions in the tumor tissue.

New results from the TROPION-Lung02 trial highlight the potential of the antibody-drug conjugate datopotamab deruxtecan with pembrolizumab for patients with advanced non–small cell lung cancer.

Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.

Patients with non–small cell lung cancer who completed definitive surgery saw clinical benefits after being treated with neoadjuvant nivolumab and chemotherapy.